Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment
- PMID: 33166735
- DOI: 10.1016/j.phrs.2020.105277
Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment
Abstract
More than 50 million people have various forms of cognitive impairment basically caused by neurodegenerative diseases, such as Alzheimer's, Parkinson's, and cerebrovascular diseases as well as stroke. Often these conditions coexist and exacerbate one another. The damaged area in post-stroke dementia may lead to neurodegenerative lesions. Gut microbiome functions like an endocrine organ by generating bioactive metabolites that can directly or indirectly impact human physiology. An alteration in the composition and function of intestinal flora, i.e. gut dysbiosis, is implicated in neurodegenerative and cerebrovascular diseases. Additionally, gut dysbiosis may accelerate the progression of cognitive impairment. Dysbiosis may result from obesity; metabolic disorders, cardiovascular disease, and sleep disorders, Lack of physical activity is associated with dysbiosis as well. These may coexist in various patterns in older people, enhancing the risk, incidence, and progression of cerebrovascular lesions, neurodegenerative disorders, and cognitive impairment, creating a vicious circle. Recently, it has been reported that several metabolites produced by gut microbiota (e.g., trimethylamine/trimethylamine N-oxide, short-chain fatty acids, secondary bile acids) may be linked to neurodegenerative and cerebrovascular diseases. New treatment modalities, including prebiotic and probiotics, may normalize the gut microbiota composition, change the brain-gut barrier, and decrease the risk of the pathology development. Fecal microbiota transplantation, sometimes in combination with other methods, is used for remodeling and replenishing the symbiotic gut microbiome. This promising field of research is associated with basic findings of bidirectional communication between body organs and gut microbiota that creates new possibilities of pharmacological treatments of many clinical conditions. The authors present the role of gut microbiota in physiology, and the novel therapeutic targets in modulation of intestinal microbiota Personalized therapies based on their personal genome make up could offer benefits by modulating microbiota cross-talk with brain and cardiovascular system. A healthy lifestyle, including pre and probiotic nutrition is generally recommended. Prevention may also be enhanced by correcting gut dysbiosis resulting a reduced risk of post-stroke cognitive impairment including dementia.
Keywords: Cognitive impairment; Microbiome; Neurodegeneration; Nutrition; Obesity; Stroke.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Similar articles
-
[Correction of gut dysbiosis as a promising direction in the prevention of neuroinflammation and cognitive impairment].Vopr Pitan. 2023;92(6):107-119. doi: 10.33029/0042-8833-2023-92-6-107-119. Epub 2023 Oct 30. Vopr Pitan. 2023. PMID: 38198424 Russian.
-
Probiotic Clostridium butyricum ameliorates cognitive impairment in obesity via the microbiota-gut-brain axis.Brain Behav Immun. 2024 Jan;115:565-587. doi: 10.1016/j.bbi.2023.11.016. Epub 2023 Nov 17. Brain Behav Immun. 2024. PMID: 37981012
-
Gut Microbiota and Alzheimer's Disease: Pathophysiology and Therapeutic Perspectives.J Alzheimers Dis. 2021;83(3):963-976. doi: 10.3233/JAD-210381. J Alzheimers Dis. 2021. PMID: 34366348 Review.
-
Role of the Gut Microbiota in Stroke Pathogenesis and Potential Therapeutic Implications.Ann Nutr Metab. 2021;77 Suppl 2(Suppl 2):36-44. doi: 10.1159/000516398. Epub 2021 Jun 9. Ann Nutr Metab. 2021. PMID: 34107468 Free PMC article. Review.
-
Gut microbiota is causally associated with poststroke cognitive impairment through lipopolysaccharide and butyrate.J Neuroinflammation. 2022 Apr 4;19(1):76. doi: 10.1186/s12974-022-02435-9. J Neuroinflammation. 2022. PMID: 35379265 Free PMC article.
Cited by
-
Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells.Cancers (Basel). 2022 May 12;14(10):2381. doi: 10.3390/cancers14102381. Cancers (Basel). 2022. PMID: 35625986 Free PMC article. Review.
-
Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review).Mol Med Rep. 2021 Oct;24(4):734. doi: 10.3892/mmr.2021.12374. Epub 2021 Aug 20. Mol Med Rep. 2021. PMID: 34414447 Free PMC article. Review.
-
The Microbiota-Gut-Brain Axis and Alzheimer Disease. From Dysbiosis to Neurodegeneration: Focus on the Central Nervous System Glial Cells.J Clin Med. 2021 May 27;10(11):2358. doi: 10.3390/jcm10112358. J Clin Med. 2021. PMID: 34072107 Free PMC article. Review.
-
Novel Mechanisms and Therapeutic Targets for Ischemic Stroke: A Focus on Gut Microbiota.Front Cell Neurosci. 2022 May 17;16:871720. doi: 10.3389/fncel.2022.871720. eCollection 2022. Front Cell Neurosci. 2022. PMID: 35656406 Free PMC article. Review.
-
Dysbiosis of Gut Microbiota from the Perspective of the Gut-Brain Axis: Role in the Provocation of Neurological Disorders.Metabolites. 2022 Nov 3;12(11):1064. doi: 10.3390/metabo12111064. Metabolites. 2022. PMID: 36355147 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical